Epitalon reduced malignant tumors and eliminated metastases in aging female C3H/He mice
Background
Spontaneous carcinogenesis in aging rodent models presents a critical window for evaluating oncostatic peptide interventions before human trials. The pineal gland produces regulatory peptides hypothesized to modulate tumor progression through neuroendocrine pathways, yet synthetic analogs have seen limited systematic oncology study. Mammary gland and ovarian tumors are predominant spontaneous malignancies in the C3H/He mouse strain, making it a relevant model for reproductive-organ carcinogenesis. Existing standard-of-care approaches offer little for primary cancer prevention in aging populations, creating demand for low-dose, low-toxicity preventive agents. Epitalon, a tetrapeptide (Ala-Glu-Asp-Gly) derived from the pineal peptide preparation epithalamin, is under investigation for its putative oncostatic and antimetastatic properties.
Study Design
One-year-old female C3H/He mice were divided into a control arm and an experimental arm receiving Epitalon (Ala-Glu-Asp-Gly) at 0.1 µg via injection, 5 times per week over 6.5 months under standard housing conditions. The primary endpoints were incidence of malignant tumor-bearing mice, tumor type distribution across organs, and presence of metastases. Histopathological classification distinguished invasive ductal carcinomas of the mammary gland from granulosa-cell tumors of the ovaries, and benign tumors in other organs. Toxicity was monitored throughout the treatment period.
Results
Treatment with Epitalon decreased the number of tumor-bearing mice carrying malignant tumors relative to controls, with spontaneous tumors of the reproductive organs — mammary glands and ovaries — predominating in both groups. Mammary gland tumors were identified histologically as different variants of invasive ductal carcinomas, while ovarian tumors were classified as granulosa-cell tumors. Tumors in other organs were in the minority and displayed benign characteristics in both arms. In the control group, metastases were detected in 3 out of 9 tumor-bearing mice, all originating from reproductive-organ tumors.
Zero metastases were found in any Epitalon-treated mouse, demonstrating a complete antimetastatic effect in this model.
Long-term exposure to Epitalon at 0.1 µg showed no toxic effect, supporting the tolerability of the dosing regimen across the 6.5-month observation window.
Key Findings
- Epitalon decreased the number of malignant tumor-bearing mice vs. untreated controls over 6.5 months
- Metastases found in 3 out of 9 control tumor-bearing mice; zero metastases in Epitalon-treated mice
- Predominant tumor types: invasive ductal carcinomas (mammary) and granulosa-cell tumors (ovary) in both groups
- No toxic effects observed with 0.1 µg injections 5 times per week over the full 6.5-month treatment period
- Tumors in non-reproductive organs were minority occurrences and exhibited benign characteristics in both arms
Why It Matters
Epitalon's complete suppression of metastasis in this aging mouse model is a clinically meaningful signal — metastatic spread, not primary tumor growth alone, drives the majority of cancer mortality. For peptide researchers and clinicians, the data suggest that low-dose, high-frequency Epitalon administration (0.1 µg × 5 days/week) can be maintained for months without detectable toxicity, which is a prerequisite for any preventive protocol. The antimetastatic finding elevates Epitalon's profile beyond its established telomerase-activating and anti-aging associations, pointing toward a plausible oncostatic mechanism worth isolating in mechanistic follow-up. Translation to humans remains distant: this is a spontaneous-tumor model in a single inbred mouse strain, and dose scaling, route equivalency, and biomarker endpoints have not been established for clinical use.
TitrateLab articles covering Epitalon
Written by TitrateLab, separately from the study summarized above.
